Clinical trial
A Prospective, Randomized, Open Label, Parallel, 16-week Study to Explore and Evaluate the Therapeutic Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese Patients With T2DM Inadequately Controlled With Metformin Monotherapy.
NCT03961659 is registered in ClinicalTrials.gov with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Open Label, Parallel, 16-week Study to Explore and Evaluate the Therapeutic Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese Patients With T2DM Inadequately Controlled With Metformin Monotherapy.
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- May 31, 2019
- Completion date
- February 28, 2021
- Enrollment
- 87 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cognitive impairment, obesity, type 2 diabetes mellitus